Algo version: 0.98b
JW THERAP-B is listed at the HKSE Exchange
JW THERAP-B [2126.HK]
HKSE Sector: Healthcare Industry:Biotechnology

Is JW THERAP-B stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

We cannot find any recorded dividends paid in our systems.

Sorry, we do not have any analyst data for this ticker

We cannot find data for JW THERAP-B 10 years ago, but if you had invested on Tuesday 3rd of November 2020 when the price was HKD22.00, you would have made a loss of HKD-20.64 per share or -93.82%

No, the average daily trading liquidity for JW THERAP-B is HKD276 140 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

JW THERAP-B has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for JW THERAP-B to be high [0.85 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.